About this Journal Submit a Manuscript Table of Contents
Journal of Biomedicine and Biotechnology
Volume 2010 (2010), Article ID 218752, 10 pages
http://dx.doi.org/10.1155/2010/218752
Review Article

Delivery of Exogenous Antigens to Induce Cytotoxic CD8+ T Lymphocyte Responses

Department of Microbiology and Immunology, Queen's University, Kingston, ON, Canada K7L 3N6

Received 11 December 2009; Accepted 9 March 2010

Academic Editor: Kim Klonowski

Copyright © 2010 Julia Kim et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. S. Shresta, C. T. Pham, D. A. Thomas, T. A. Graubert, and T. J. Ley, “How do cytotoxic lymphocytes kill their targets?” Current Opinion in Immunology, vol. 10, no. 5, pp. 581–587, 1998. View at Publisher · View at Google Scholar · View at Scopus
  2. C. J. M. Melief and W. M. Kast, “Cytotoxic T lymphocyte therapy of cancer and tumor escape mechanisms,” Seminars in Cancer Biology, vol. 2, no. 5, pp. 347–354, 1991. View at Scopus
  3. J. T. Harty, R. D. Schreiber, and M. J. Bevan, “CD8 T cells can protect against an intracellular bacterium in an interferon γ-independent fashion,” Proceedings of the National Academy of Sciences of the United States of America, vol. 89, no. 23, pp. 11612–11616, 1992. View at Publisher · View at Google Scholar · View at Scopus
  4. S. Basta and A. Alatery, “The cross-priming pathway: a portrait of an intricate immune system,” Scandinavian Journal of Immunology, vol. 65, no. 4, pp. 311–319, 2007. View at Publisher · View at Google Scholar · View at Scopus
  5. W. R. Heath, G. T. Belz, G. M. N. Behrens, et al., “Cross-presentation, dendritic cell subsets, and the generation of immunity to cellular antigens,” Immunological Reviews, vol. 199, pp. 9–26, 2004. View at Publisher · View at Google Scholar · View at Scopus
  6. J. W. Yewdell and S. M. M. Haeryfar, “Understanding presentation of viral antigens to CD8+ T cells in vivo: the key to rational vaccine design,” Annual Review of Immunology, vol. 23, pp. 651–682, 2005. View at Publisher · View at Google Scholar · View at Scopus
  7. L. Shen and K. L. Rock, “Priming of T cells by exogenous antigen cross-presented on MHC class I molecules,” Current Opinion in Immunology, vol. 18, no. 1, pp. 85–91, 2006. View at Publisher · View at Google Scholar · View at Scopus
  8. S. Basta and J. R. Bennink, “A survival game of hide and seek: cytomegaloviruses and MHC class I antigen presentation pathways,” Viral Immunology, vol. 16, no. 3, pp. 231–242, 2003. View at Scopus
  9. R. G. van der Most, A. Currie, B. W. S. Robinson, and R. A. Lake, “Cranking the immunologic engine with chemotherapy: using context to drive tumor antigen cross-presentation towards useful antitumor immunity,” Cancer Research, vol. 66, no. 2, pp. 601–604, 2006. View at Publisher · View at Google Scholar · View at Scopus
  10. A. H. Sharpe, “Mechanisms of costimulation,” Immunological Reviews, vol. 229, no. 1, pp. 5–11, 2009. View at Publisher · View at Google Scholar · View at Scopus
  11. J. Valenzuela, C. Schmidt, and M. F. Mescher, “The roles of IL-12 in providing a third signal for clonal expansion of naive CD8 T cells,” The Journal of Immunology, vol. 169, no. 12, pp. 6842–6849, 2002. View at Scopus
  12. J. M. Curtsinger, J. O. Valenzuela, P. Agarwal, D. Lins, and M. F. Mescher, “Cutting edge: type I IFNs provide a third signal to CD8 T cells to stimulate clonal expansion and differentiation,” The Journal of Immunology, vol. 174, no. 8, pp. 4465–4469, 2005. View at Scopus
  13. M. F. Mescher, P. Agarwal, K. A. Casey, C. D. Hammerbeck, Z. Xiao, and J. M. Curtsinger, “Molecular basis for checkpoints in the CD8 T cell response: tolerance versus activation,” Seminars in Immunology, vol. 19, no. 3, pp. 153–161, 2007. View at Publisher · View at Google Scholar · View at Scopus
  14. Z. Xiao, K. A. Casey, S. C. Jameson, J. M. Curtsinger, and M. F. Mescher, “Programming for CD8 T cell memory development requires IL-120 or type I IFN,” The Journal of Immunology, vol. 182, no. 5, pp. 2786–2794, 2009. View at Publisher · View at Google Scholar · View at Scopus
  15. K. L. Rock, I. A. York, T. Saric, and A. L. Goldberg, “Protein degradation and the generation of MHC class I-presented peptides,” Advances in Immunology, vol. 80, pp. 1–70, 2002. View at Publisher · View at Google Scholar · View at Scopus
  16. J. W. Yewdell, E. Reits, and J. Neefjes, “Making sense of mass destruction: quantitating MHC class I antigen presentation,” Nature Reviews Immunology, vol. 3, no. 12, pp. 952–961, 2003. View at Scopus
  17. S. Basta, R. Stoessel, M. Basler, M. van den Broek, and M. Groettrup, “Cross-presentation of the long-lived lymphocytic choriomeningitis virus nucleoprotein does not require neosynthesis and is enhanced via heat shock proteins,” The Journal of Immunology, vol. 175, no. 2, pp. 796–805, 2005. View at Scopus
  18. J. F. Fonteneau, D. G. Kavanagh, M. Lirvall, et al., “Characterization of the MHC class I cross-presentation pathway for cell-associated antigens by human dendritic cells,” Blood, vol. 102, no. 13, pp. 4448–4455, 2003. View at Publisher · View at Google Scholar · View at Scopus
  19. F. R. Carbone and M. J. Bevan, “Class I-restricted processing and presentation of exogenous cell-associated antigen in vivo,” Journal of Experimental Medicine, vol. 171, no. 2, pp. 377–387, 1990. View at Scopus
  20. J. D. Pfeifer, M. J. Wick, R. L. Roberts, K. Findlay, S. J. Normark, and C. V. Harding, “Phagocytic processing of bacterial antigens for class I MHC presentation to T cells,” Nature, vol. 361, no. 6410, pp. 359–362, 1993. View at Publisher · View at Google Scholar · View at Scopus
  21. W. Chen, K.-A. Masterman, S. Basta, et al., “Cross-priming of CD8+ T cells by viral and tumor antigens is a robust phenomenon,” European Journal of Immunology, vol. 34, no. 1, pp. 194–199, 2004. View at Publisher · View at Google Scholar · View at Scopus
  22. K. Shimizu, Y. Kurosawa, M. Taniguchi, R. M. Steinman, and S.-I. Fujii, “Cross-presentation of glycolipid from tumor cells loaded with α-galactosylceramide leads to potent and long-lived T cell-mediated immunity via dendritic cells,” Journal of Experimental Medicine, vol. 204, no. 11, pp. 2641–2653, 2007. View at Publisher · View at Google Scholar · View at Scopus
  23. Y. Li, L.-X. Wang, P. Pang, et al., “Cross-presentation of tumor associated antigens through tumor-derived autophagosomes,” Autophagy, vol. 5, no. 4, pp. 576–577, 2009. View at Publisher · View at Google Scholar · View at Scopus
  24. S. Basta, W. Chen, J. R. Bennink, and J. W. Yewdell, “Inhibitory effects of cytomegalovirus proteins US2 and US11 point to contributions from direct priming and cross-priming in induction of vaccinia virus-specific CD8+ T cells,” The Journal of Immunology, vol. 168, no. 11, pp. 5403–5408, 2002. View at Scopus
  25. A. Serna, M. C. Ramirez, A. Soukhanova, and L. J. Sigal, “Cutting edge: efficient MHC class I cross-presentation during early vaccinia infection requires the transfer of proteasomal intermediates between antigen donor and presenting cells,” The Journal of Immunology, vol. 171, no. 11, pp. 5668–5672, 2003. View at Scopus
  26. O. Schulz, S. S. Diebold, M. Chen, et al., “Toll-like receptor 3 promotes cross-priming to virus-infected cells,” Nature, vol. 433, no. 7028, pp. 887–892, 2005. View at Publisher · View at Google Scholar · View at Scopus
  27. R. S. Goldszmid, I. Coppens, A. Lev, P. Caspar, I. Mellman, and A. Sher, “Host ER-parasitophorous vacuole interaction provides a route of entry for antigen cross-presentation in Toxoplasma gondii-infected dendritic cells,” Journal of Experimental Medicine, vol. 206, no. 2, pp. 399–410, 2009. View at Publisher · View at Google Scholar · View at Scopus
  28. C. C. Norbury, S. Basta, K. B. Donohue, et al., “CD8+ T cell cross-priming via transfer of proteasome substrates,” Science, vol. 304, no. 5675, pp. 1318–1321, 2004. View at Publisher · View at Google Scholar · View at Scopus
  29. L. Shen and K. L. Rock, “Cellular protein is the source of cross-priming antigen in vivo,” Proceedings of the National Academy of Sciences of the United States of America, vol. 101, no. 9, pp. 3035–3040, 2004. View at Publisher · View at Google Scholar · View at Scopus
  30. A. D. Bins, M. C. Wolkers, M. D. van den Boom, J. B. A. G. Haanen, and T. N. M. Schumacher, “In vivo antigen stability affects DNA vaccine immunogenicity,” The Journal of Immunology, vol. 179, no. 4, pp. 2126–2133, 2007. View at Scopus
  31. M. C. Wolkers, N. Brouwenstijn, A. H. Bakker, M. Toebes, and T. N. M. Schumacher, “Antigen bias in T cell cross-priming,” Science, vol. 304, no. 5675, pp. 1314–1317, 2004. View at Publisher · View at Google Scholar · View at Scopus
  32. M. Li, G. M. Davey, R. M. Sutherland, et al., “Cell-associated ovalbumin is cross-presented much more efficiently than soluble ovalbumin in vivo,” The Journal of Immunology, vol. 166, no. 10, pp. 6099–6103, 2001. View at Scopus
  33. M. Kovacsovics-Bankowski, K. Clark, B. Benacerraf, and K. L. Rock, “Efficient major histocompatibility complex class I presentation of exogenous antigen upon phagocytosis by macrophages,” Proceedings of the National Academy of Sciences of the United States of America, vol. 90, no. 11, pp. 4942–4946, 1993. View at Scopus
  34. L. J. Sigal and K. L. Rock, “Bone marrow-derived antigen-presenting cells are required for the generation of cytotoxic T lymphocyte responses to viruses and use transporter associated with antigen presentation (TAP)-dependent and -independent pathways of antigen presentation,” Journal of Experimental Medicine, vol. 192, no. 8, pp. 1143–1150, 2000. View at Publisher · View at Google Scholar · View at Scopus
  35. L. J. Sigal, S. Crotty, R. Andino, and K. L. Rock, “Cytotoxic T-cell immunity to virus-infected non-haematopoietic cells requires presentation of exogenous antigen,” Nature, vol. 398, no. 6722, pp. 77–80, 1999. View at Publisher · View at Google Scholar · View at Scopus
  36. A. Y. Huang, P. Golumbek, M. Ahmadzadeh, E. Jaffee, D. Pardoll, and H. Levitsky, “Bone marrow-derived cells present MHC class I-restricted tumour antigens in priming of antitumour immune responses,” Ciba Foundation Symposium, vol. 187, pp. 229–244, 1994.
  37. A. Alatery, S. Siddiqui, M. Chan, A. Kus, E. O. Petrof, and S. Basta, “Cross, but not direct, presentation of cell-associated virus antigens by spleen macrophages is influenced by their differentiation state,” Immunology and Cell Biology, vol. 88, no. 1, pp. 3–12, 2010. View at Publisher · View at Google Scholar · View at Scopus
  38. A. L. Ackerman and P. Cresswell, “Cellular mechanisms governing cross-presentation of exogenous antigens,” Nature Immunology, vol. 5, no. 7, pp. 678–684, 2004. View at Publisher · View at Google Scholar · View at Scopus
  39. S. Burgdorf, C. Scholz, A. Kautz, R. Tampe, and C. Kurts, “Spatial and mechanistic separation of cross-presentation and endogenous antigen presentation,” Nature Immunology, vol. 9, no. 5, pp. 558–566, 2008. View at Publisher · View at Google Scholar · View at Scopus
  40. C. Kurts, H. Kosaka, F. R. Carbone, J. F. A. P. Miller, and W. R. Heath, “Class I-restricted cross-presentation of exogenous self-antigens leads to deletion of autoreactive CD8+ T cells,” Journal of Experimental Medicine, vol. 186, no. 2, pp. 239–245, 1997. View at Publisher · View at Google Scholar · View at Scopus
  41. A. Limmer, J. Ohl, C. Kurts, et al., “Efficient presentation of exogenous antigen by liver endothelial cells to CD8+ T cells results in antigen-specific T-cell tolerance,” Nature Medicine, vol. 6, no. 12, pp. 1348–1354, 2000. View at Publisher · View at Google Scholar · View at Scopus
  42. A. Schildknecht, H. C. Probst, K. D. McCoy, et al., “Antigens expressed by myelinating glia cells induce peripheral cross-tolerance of endogenous CD8+ T cells,” European Journal of Immunology, vol. 39, no. 6, pp. 1505–1515, 2009. View at Publisher · View at Google Scholar · View at Scopus
  43. M. B. Lutz and C. Kurts, “Induction of peripheral CD4+ T-cell tolerance and CD8+ T-cell cross-tolerance by dendritic cells,” European Journal of Immunology, vol. 39, no. 9, pp. 2325–2330, 2009. View at Publisher · View at Google Scholar · View at Scopus
  44. W. L. Redmond, C.-H. Wei, H. T. C. Kreuwel, and L. A. Sherman, “The apoptotic pathway contributing to the deletion of naive CD8 T cells during the induction of peripheral tolerance to a cross-presented self-antigen,” The Journal of Immunology, vol. 180, no. 8, pp. 5275–5282, 2008. View at Scopus
  45. A. Limmer, J. Ohl, G. Wingender, et al., “Cross-presentation of oral antigens by liver sinusoidal endothelial cells leads to CD8 T cell tolerance,” European Journal of Immunology, vol. 35, no. 10, pp. 2970–2981, 2005. View at Publisher · View at Google Scholar · View at Scopus
  46. I. Mellman and R. M. Steinman, “Dendritic cells: specialized and regulated antigen processing machines,” Cell, vol. 106, no. 3, pp. 255–258, 2001. View at Publisher · View at Google Scholar · View at Scopus
  47. J. K. Northrop and H. Shen, “CD8+ T-cell memory: only the good ones last,” Current Opinion in Immunology, vol. 16, no. 4, pp. 451–455, 2004. View at Publisher · View at Google Scholar · View at Scopus
  48. M. T. Esser, R. D. Marchese, L. S. Kierstead, et al., “Memory T cells and vaccines,” Vaccine, vol. 21, no. 5-6, pp. 419–430, 2003. View at Publisher · View at Google Scholar · View at Scopus
  49. J. W. Yewdell, “Confronting complexity: real-world immunodominance in antiviral CD8+ T cell responses,” Immunity, vol. 25, no. 4, pp. 533–543, 2006. View at Publisher · View at Google Scholar · View at Scopus
  50. E. Dunbar, A. Alatery, and S. Basta, “Cross-priming of a single viral protein from lymphocytic choriomeningitis virus alters immunodominance hierarchies of CD8+ T cells during subsequent viral infections,” Viral Immunology, vol. 20, no. 4, pp. 585–598, 2007. View at Publisher · View at Google Scholar · View at Scopus
  51. V. Pavelic, M. Matter, S. Mumprecht, I. Breyer, and A. F. Ochsenbein, “CTL induction by cross-priming is restricted to immunodominant epitopes,” European Journal of Immunology, vol. 39, no. 3, pp. 704–716, 2009. View at Publisher · View at Google Scholar · View at Scopus
  52. P. Otahal, S. C. Hutchinson, L. M. Mylin, M. J. Tevethia, S. S. Tevethia, and T. D. Schell, “Inefficient cross-presentation limits the CD8+ T cell response to a subdominant tumor antigen epitope,” The Journal of Immunology, vol. 175, no. 2, pp. 700–712, 2005. View at Scopus
  53. Y. Wang, I. E. A. Flesch, and D. C. Tscharke, “Vaccinia virus CD8+ T-cell dominance hierarchies cannot be altered by prior immunization with individual peptides,” Journal of Virology, vol. 83, no. 17, pp. 9008–9012, 2009. View at Publisher · View at Google Scholar · View at Scopus
  54. A. Heit, D. H. Busch, H. Wagner, and F. Schmitz, “Vaccine protocols for enhanced immunogenicity of exogenous antigens,” International Journal of Medical Microbiology, vol. 298, no. 1-2, pp. 27–32, 2008. View at Publisher · View at Google Scholar · View at Scopus
  55. A. Heit, F. Schmitz, M. O'Keeffe, et al., “Protective CD8 T cell immunity triggered by CpG-protein conjugates competes with the efficacy of live vaccines,” The Journal of Immunology, vol. 174, no. 7, pp. 4373–4380, 2005. View at Scopus
  56. K. Zaks, M. Jordan, A. Guth, et al., “Efficient immunization and cross-priming by vaccine adjuvants containing TLR3 or TLR9 agonists complexed to cationic liposomes,” The Journal of Immunology, vol. 176, no. 12, pp. 7335–7345, 2006. View at Scopus
  57. S. Hervas-Stubbs, A. Olivier, F. Boisgerault, N. Thieblemont, and C. Leclerc, “TLR3 ligand stimulates fully functional memory CD8+ T cells in the absence of CD4+ T-cell help,” Blood, vol. 109, no. 12, pp. 5318–5326, 2007. View at Publisher · View at Google Scholar · View at Scopus
  58. A. Heit, T. Maurer, H. Hochrein, et al., “Cutting edge: Toll-like receptor 9 expression is not required for CpG DNA-aided cross-presentation of DNA-conjugated antigens but essential for cross-priming of CD8 T cells,” The Journal of Immunology, vol. 170, no. 6, pp. 2802–2805, 2003. View at Scopus
  59. A. Heit, K. M. Huster, F. Schmitz, M. Schiemann, D. H. Busch, and H. Wagner, “CpG-DNA aided cross-priming by cross-presenting B cells,” The Journal of Immunology, vol. 172, no. 3, pp. 1501–1507, 2004. View at Scopus
  60. A. Heit, F. Schmitz, T. Haas, D. H. Busch, and H. Wagner, “Antigen co-encapsulated with adjuvants efficiently drive protective T cell immunity,” European Journal of Immunology, vol. 37, no. 8, pp. 2063–2074, 2007. View at Publisher · View at Google Scholar · View at Scopus
  61. E. Y. Enioutina, D. Bareyan, and R. A. Daynes, “TLR-induced local metabolism of vitamin D3 plays an important role in the diversification of adaptive immune responses,” The Journal of Immunology, vol. 182, no. 7, pp. 4296–4305, 2009. View at Publisher · View at Google Scholar · View at Scopus
  62. E. Y. Enioutina, D. Bareyan, and R. A. Daynes, “TLR ligands that stimulate the metabolism of vitamin D3 in activated murine dendritic cells can function as effective mucosal adjuvants to subcutaneously administered vaccines,” Vaccine, vol. 26, no. 5, pp. 601–613, 2008. View at Publisher · View at Google Scholar · View at Scopus
  63. R. A. Daynes, E. Y. Enioutina, S. Butler, H.-H. Mu, Z. A. McGee, and B. A. Araneo, “Induction of common mucosal immunity by hormonally immunomodulated peripheral immunization,” Infection and Immunity, vol. 64, no. 4, pp. 1100–1109, 1996. View at Scopus
  64. E. V. L. Grgacic and D. A. Anderson, “Virus-like particles: passport to immune recognition,” Methods, vol. 40, no. 1, pp. 60–65, 2006. View at Publisher · View at Google Scholar · View at Scopus
  65. C. Sedlik, M.-F. Saron, J. Sarraseca, I. Casal, and C. Leclerc, “Recombinant parvovirus-like particles as an antigen carrier: a novel nonreplicative exogenous antigen to elicit protective antiviral cytotoxic T cells,” Proceedings of the National Academy of Sciences of the United States of America, vol. 94, no. 14, pp. 7503–7508, 1997. View at Publisher · View at Google Scholar · View at Scopus
  66. T. Storni, C. Ruedl, K. Schwarz, R. A. Schwendener, W. A. Renner, and M. F. Bachmann, “Nonmethylated CG motifs packaged into virus-like particles induce protective cytotoxic T cell responses in the absence of systemic side effects,” The Journal of Immunology, vol. 172, no. 3, pp. 1777–1785, 2004. View at Scopus
  67. D. Leclerc, D. Beauseigle, J. Denis, et al., “Proteasome-independent major histocompatibility complex class I cross-presentation mediated by papaya mosaic virus-like particles leads to expansion of specific human T cells,” Journal of Virology, vol. 81, no. 3, pp. 1319–1326, 2007. View at Publisher · View at Google Scholar · View at Scopus
  68. S. C. Fausch, D. M. Da Silva, and W. M. Kast, “Differential uptake and cross-presentation of human papillomavirus virus-like particles by dendritic cells and Langerhans cells,” Cancer Research, vol. 63, no. 13, pp. 3478–3482, 2003. View at Scopus
  69. C. Ruedl, T. Storni, F. Lechner, T. Bachi, and M. F. Bachmann, “Cross-presentation of virus-like particles by skin-derived CD8- dendritic cells: a dispensable role for TAP,” European Journal of Immunology, vol. 32, no. 3, pp. 818–825, 2002. View at Publisher · View at Google Scholar · View at Scopus
  70. X. Paliard, Y. Liu, R. Wagner, H. Wolf, J. Baenziger, and C. M. Walker, “Priming of strong, broad, and long-lived HIV type 1 p55(gag)-specific CD8+ cytotoxic T cells after administration of a virus-like particle vaccine in rhesus macaques,” AIDS Research and Human Retroviruses, vol. 16, no. 3, pp. 273–282, 2000. View at Publisher · View at Google Scholar · View at Scopus
  71. P. Lacasse, J. Denis, R. Lapointe, D. Leclerc, and A. Lamarre, “Novel plant virus-based vaccine induces protective cytotoxic T-lymphocyte-mediated antiviral immunity through dendritic cell maturation,” Journal of Virology, vol. 82, no. 2, pp. 785–794, 2008. View at Publisher · View at Google Scholar · View at Scopus
  72. V. G. Moron, P. Rueda, C. Sedlik, and C. Leclerc, “In vivo, dendritic cells can cross-present virus-like particles using an endosome-to-cytosol pathway,” The Journal of Immunology, vol. 171, no. 5, pp. 2242–2250, 2003. View at Scopus
  73. W. Bohm, R. Schirmbeck, A. Elbe, et al., “Exogenous hepatitis B surface antigen particles processed by dendritic cells or macrophages prime murine MHC class I-restricted cytotoxic T lymphocytes in vivo,” The Journal of Immunology, vol. 155, no. 7, pp. 3313–3321, 1995. View at Scopus
  74. P. Di Bonito, F. Grasso, S. Mochi, et al., “Anti-tumor CD8+ T cell immunity elicited by HIV-1-based virus-like particles incorporating HPV-16 E7 protein,” Virology, vol. 395, no. 1, pp. 45–55, 2009. View at Publisher · View at Google Scholar · View at Scopus
  75. Y. Krishnamachari and A. K. Salem, “Innovative strategies for co-delivering antigens and CpG oligonucleotides,” Advanced Drug Delivery Reviews, vol. 61, no. 3, pp. 205–217, 2009. View at Publisher · View at Google Scholar · View at Scopus
  76. M. Singh and D. T. O'Hagan, “Recent advances in vaccine adjuvants,” Pharmaceutical Research, vol. 19, no. 6, pp. 715–728, 2002. View at Publisher · View at Google Scholar · View at Scopus
  77. X.-Q. Zhang, C. E. Dahle, N. K. Baman, N. Rich, G. J. Weiner, and A. K. Salem, “Potent antigen-specific immune responses stimulated by codelivery of CpG ODN and antigens in degradable microparticles,” Journal of Immunotherapy, vol. 30, no. 5, pp. 469–478, 2007. View at Publisher · View at Google Scholar · View at Scopus
  78. M. E. Keegan and W. M. Saltzman, “Surface-modified biodegradable microspheres for DNA vaccine delivery,” Methods in Molecular Medicine, vol. 127, pp. 107–113, 2006. View at Scopus
  79. Y. Waeckerle-Men and M. Groettrup, “PLGA microspheres for improved antigen delivery to dendritic cells as cellular vaccines,” Advanced Drug Delivery Reviews, vol. 57, no. 3, pp. 475–482, 2005. View at Publisher · View at Google Scholar · View at Scopus
  80. F. Boisgerault, P. Rueda, C. M. Sun, S. Hervas-Stubbs, M. Rojas, and C. Leclerc, “Cross-priming of T cell responses by synthetic microspheres carrying a CD8+ T cell epitope requires an adjuvant signal,” The Journal of Immunology, vol. 174, no. 6, pp. 3432–3439, 2005. View at Scopus
  81. S. R. M. Bennett, F. R. Carbone, F. Karamalis, J. F. A. P. Miller, and W. R. Heath, “Induction of a CD8+ cytotoxic T lymphocyte response by cross-priming requires cognate CD4+ T cell help,” Journal of Experimental Medicine, vol. 186, no. 1, pp. 65–70, 1997. View at Publisher · View at Google Scholar · View at Scopus
  82. S. R. M. Bennett, F. R. Carbone, F. Karamalis, R. A. Flavell, J. F. A. P. Miller, and W. R. Heath, “Help for cytotoxic-T-cell responses is mediated by CD4O signalling,” Nature, vol. 393, no. 6684, pp. 478–480, 1998. View at Scopus
  83. Y. Waeckerle-Men, E. Scandella, E. Uetz-Von Allmen, et al., “Phenotype and functional analysis of human monocyte-derived dendritic cells loaded with biodegradable poly(lactide-co-glycolide) microspheres for immunotherapy,” Journal of Immunological Methods, vol. 287, no. 1-2, pp. 109–124, 2004. View at Publisher · View at Google Scholar · View at Scopus
  84. E. Schlosser, M. Mueller, S. Fischer, et al., “TLR ligands and antigen need to be coencapsulated into the same biodegradable microsphere for the generation of potent cytotoxic T lymphocyte responses,” Vaccine, vol. 26, no. 13, pp. 1626–1637, 2008. View at Publisher · View at Google Scholar · View at Scopus
  85. L. Krishnan, K. Gurnani, C. J. Dicaire, et al., “Rapid clonal expansion and prolonged maintenance of memory CD8+ T cells of the effector (CD44highCD62Llow) and central (CD44highCD62Llow) phenotype by an archaeosome adjuvant independent of TLR2,” The Journal of Immunology, vol. 178, no. 4, pp. 2396–2406, 2007. View at Scopus
  86. D. H. Busch, I. M. Pilip, S. Vijh, and E. G. Pamer, “Coordinate regulation of complex T cell populations responding to bacterial infection,” Immunity, vol. 8, no. 3, pp. 353–362, 1998. View at Publisher · View at Google Scholar · View at Scopus
  87. A. Badiee, N. Davies, K. McDonald, et al., “Enhanced delivery of immunoliposomes to human dendritic cells by targeting the multilectin receptor DEC-205,” Vaccine, vol. 25, no. 25, pp. 4757–4766, 2007. View at Publisher · View at Google Scholar · View at Scopus
  88. A. Badiee, M. R. Jaafari, and A. Khamesipour, “Leishmania major: immune response in BALB/c mice immunized with stress-inducible protein 1 encapsulated in liposomes,” Experimental Parasitology, vol. 115, no. 2, pp. 127–134, 2007. View at Publisher · View at Google Scholar · View at Scopus
  89. L. Krishnan and G. D. Sprott, “Archaeosome adjuvants: immunological capabilities and mechanism(s) of action,” Vaccine, vol. 26, no. 17, pp. 2043–2055, 2008. View at Publisher · View at Google Scholar · View at Scopus
  90. L. Krishnan, C. J. Dicaire, G. B. Patel, and G. D. Sprott, “Archaeosome vaccine adjuvants induce strong humoral, cell-mediated, and memory responses: comparison to conventional liposomes and alum,” Infection and Immunity, vol. 68, no. 1, pp. 54–63, 2000. View at Scopus
  91. K. Gurnani, J. Kennedy, S. Sad, G. D. Sprott, and L. Krishnan, “Phosphatidylserine receptor-mediated recognition of archaeosome adjuvant promotes endocytosis and MHC class I cross-presentation of the entrapped antigen by phagosome-to-cytosol transport and classical processing,” The Journal of Immunology, vol. 173, no. 1, pp. 566–578, 2004. View at Scopus
  92. L. Krishnan, S. Sad, G. B. Patel, and G. D. Sprott, “Archaeosomes induce enhanced cytotoxic T lymphocyte responses to entrapped soluble protein in the absence of interleukin 12 and protect against tumor challenge,” Cancer Research, vol. 63, no. 10, pp. 2526–2534, 2003. View at Scopus
  93. L. Krishnan, S. Sad, G. B. Patel, and G. D. Sprott, “Archaeosomes induce long-term CD8+ cytotoxic T cell response to entrapped soluble protein by the exogenous cytosolic pathway, in the absence of CD4+ T cell help,” The Journal of Immunology, vol. 165, no. 9, pp. 5177–5185, 2000. View at Scopus